Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-06-28
2005-06-28
Coleman, Brenda (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S266200, C514S266210, C514S266230, C514S266240, C544S283000, C544S284000, C544S291000, C544S292000, C544S293000
Reexamination Certificate
active
06911446
ABSTRACT:
The present invention is directed in part towards methods of modulating the function of serine/threonine protein kinases with quinazoline-based compounds. The methods incorporate cells that express a serine/threonine protein kinase, such as RAF. In addition, the invention describes methods of preventing and treating serine/threonine protein kinase-related abnormal conditions in organisms with a compound identified by the invention. Furthermore, the invention pertains to quinazoline compounds and pharmaceutical compositions comprising these compounds.
REFERENCES:
patent: 5217999 (1993-06-01), Levitzki et al.
patent: 5302606 (1994-04-01), Spada et al.
patent: 5330992 (1994-07-01), Eissenstat et al.
patent: 5430148 (1995-07-01), Webber et al.
patent: 5534518 (1996-07-01), Henrie, II et al.
patent: 5714493 (1998-02-01), Myers et al.
patent: 5866572 (1999-02-01), Barker et al.
patent: RE36256 (1999-07-01), Spada et al.
patent: 6248771 (2001-06-01), Shenoy et al.
patent: 566 226 (1993-10-01), None
patent: 91/15495 (1991-10-01), None
patent: 92/20642 (1992-11-01), None
patent: 92/21660 (1992-12-01), None
patent: 94/03427 (1994-02-01), None
patent: 94/14808 (1994-07-01), None
patent: 96/22976 (1996-08-01), None
patent: 96/40116 (1996-12-01), None
patent: 99/10325 (1999-04-01), None
Hynes et al., “Quinazolines as Inhibitors of Dihydrofolate Reductase”, Journal of Medicinal Chemistry, vol. 17 No. 9, pp. 1023-1025, (1974).
Chan et al., “Selective Inhibitors of Candida albicans Dihydrofolate Reductase: Activity and Selectivity of 5-(Arylthiol)-2,4-diaminoquinazolines”, J. of Med Chem., vol. 38, No. 18, pp. 3608-3616, (1995).
Bonner et al., “Structure and biological activity of human homologs of the raf/mil oncogene”, Molecular and Cellular Biology, 5(6):1400-1407, (1985).
Judah Folkman, “what is the evidence that tumors are angiogenesis dependent?”, J. Natl. Cancer Institute 82(1):4-6, (1990).
Harlo & Lane, Antibodies: A Laboratory manual, Cold Spring Harbor Laboratories, (1989) (Tables of Contents).
Harris et al., “Antifolate and antibacterial activities of 5-substituted 2,4-diaminoquinazolines”, J. Med. Chem. 33(1):434-44, (1990).
Hynes et al., “Direct synthesis of 2,4-Diaminoquinazolines from 2-fluorobenzonitriles”, J. Heterocyclic chem. 25:1173-1177 (1988).
Hynes et al., “further studies on the synthesis of quinazoline from 2-fluorobenzonitriles”, J. Heterocyclic Chem. 28:1357-1363, (1991).
Marsham et al., “Quinazoline Antifolate Thymidylate Synthase Inhibitors”, J. Med. Chem. 32(3):569-575, (1989).
Monia et al., “antitumor activity of a phosphorothioate antisense oligedeoxynucleotide targeted against C-raf Kinase”, Nature medicine, 2:668-675 (1996).
Morrison et al, “Signal transduction from membrane to cytolasm: Growth factors and membrane-bound Oncogene products increase Raf-1 phophorylation and associated protein kinase activity”, Proc. Natl. Acad. Sci. USA, 85:8855-8859 (1988).
Robbins et al., “Regulation and properties of extracellular signal0regulated protein kinases 1 and 2 in vitro” J. Biol. Chem., 268:5097-5106, (1993).
Webber et al., “Design of thymidylate synthase inhibitors using protein crystal structures: the synthesis and Biological evaluation of a novel class of 5-substituted quinazolinones”, J. Med. Chem., 36(6)733-746, (1993).
App Harald
Kutscher Bernhard
McMahon Gerald
Tang Peng C.
Weinberger Heinz
Burrous Beth A.
Coleman Brenda
Foley & Lardner LLP
Sugen Inc.
LandOfFree
Methods of modulating serine/threonine protein kinase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of modulating serine/threonine protein kinase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of modulating serine/threonine protein kinase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3484600